STOCK TITAN

[Form 4] Genesis Energy, L.P. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 snapshot: On 06/30/2025, Pfizer Inc. (PFE) Chairman & CEO Albert Bourla was credited with 25 Phantom Stock Units at a reference price of $24.24 under the company’s Non-funded Deferred Compensation and Supplemental Savings Plan (SSP). Each unit mirrors one share of Pfizer common stock but will be settled in cash after the executive’s separation from service and can be reallocated to other plan investments at any time.

After this routine accrual, Bourla’s total phantom-unit balance stands at 718,220 units. The filing discloses no open-market purchases or sales of Pfizer common stock, and there is no change to his direct share ownership.

Given the immaterial size of the grant (25 units) and its deferred-compensation nature, the transaction is considered administrative and non-market-moving. Investors should view the disclosure as a standard update required by Section 16 rather than a signal of management’s near-term view on Pfizer’s share price.

Riepilogo del Modulo 4: Il 30/06/2025, Albert Bourla, Presidente e CEO di Pfizer Inc. (PFE), ha ricevuto 25 Phantom Stock Units a un prezzo di riferimento di 24,24 dollari nell'ambito del Piano di Compensazione Differita Non Finanziata e Risparmio Supplementare (SSP) dell'azienda. Ogni unità rappresenta una azione ordinaria di Pfizer, ma sarà liquidata in contanti dopo la cessazione del rapporto di lavoro e può essere riallocata in altri investimenti del piano in qualsiasi momento.

Dopo questa normale assegnazione, il saldo totale delle phantom unit di Bourla è di 718.220 unità. Il documento non evidenzia acquisti o vendite sul mercato aperto di azioni Pfizer, né variazioni nella sua proprietà diretta di azioni.

Considerando la dimensione insignificante della concessione (25 unità) e la natura di compensazione differita, la transazione è considerata amministrativa e senza impatto sul mercato. Gli investitori dovrebbero interpretare questa comunicazione come un aggiornamento standard richiesto dalla Sezione 16, non come un'indicazione della visione a breve termine della dirigenza sul prezzo delle azioni Pfizer.

Resumen del Formulario 4: El 30/06/2025, Albert Bourla, Presidente y CEO de Pfizer Inc. (PFE), recibió 25 Unidades de Acciones Fantasma a un precio de referencia de 24,24 dólares bajo el Plan de Compensación Diferida No Financiada y Ahorro Suplementario (SSP) de la compañía. Cada unidad representa una acción común de Pfizer, pero se liquidará en efectivo tras la separación del ejecutivo de la empresa y puede reasignarse a otras inversiones del plan en cualquier momento.

Tras esta acumulación rutinaria, el saldo total de unidades fantasma de Bourla asciende a 718,220 unidades. La presentación no revela compras o ventas en el mercado abierto de acciones comunes de Pfizer, ni cambios en su propiedad directa de acciones.

Dada la insignificancia del otorgamiento (25 unidades) y su naturaleza de compensación diferida, la transacción se considera administrativa y sin impacto en el mercado. Los inversores deben ver esta divulgación como una actualización estándar requerida por la Sección 16, no como una señal de la perspectiva a corto plazo de la gerencia sobre el precio de las acciones de Pfizer.

Form 4 요약: 2025년 6월 30일, Pfizer Inc.(PFE) 회장 겸 CEO 알버트 보를라는 회사의 비기금 이연 보상 및 추가 저축 계획(SSP)에 따라 기준 가격 24.24달러로 25개의 팬텀 스톡 유닛을 부여받았습니다. 각 유닛은 Pfizer 보통주 1주와 동일하지만, 임원이 퇴직한 후 현금으로 정산되며 언제든지 다른 투자로 재배분할 수 있습니다.

이번 정기 적립 후 보를라의 총 팬텀 유닛 잔액은 718,220 유닛입니다. 제출 서류에는 Pfizer 보통주의 시장 내 매매 내역이 없으며, 직접 보유 주식에도 변동이 없습니다.

부여 수량이 미미한 25유닛이고 이연 보상의 성격을 고려할 때, 이 거래는 행정적이며 시장에 영향을 미치지 않는 것으로 간주됩니다. 투자자들은 이 공시를 경영진의 단기 주가 전망 신호가 아닌 섹션 16에 따른 표준 업데이트로 이해해야 합니다.

Résumé du formulaire 4 : Le 30/06/2025, Albert Bourla, président-directeur général de Pfizer Inc. (PFE), s'est vu attribuer 25 unités d’actions fantômes à un prix de référence de 24,24 $ dans le cadre du Plan de compensation différée non financé et d’épargne supplémentaire (SSP) de l’entreprise. Chaque unité correspond à une action ordinaire de Pfizer, mais sera réglementée en espèces après la séparation de l’exécutif et peut être réaffectée à d’autres investissements du plan à tout moment.

Après cette attribution routinière, le solde total des unités fantômes de Bourla s’élève à 718 220 unités. Le dépôt ne révèle aucun achat ou vente sur le marché ouvert d’actions ordinaires Pfizer, et il n’y a aucun changement dans sa détention directe d’actions.

Compte tenu de la taille négligeable de cette attribution (25 unités) et de sa nature de compensation différée, la transaction est considérée comme administrative et sans impact sur le marché. Les investisseurs doivent considérer cette divulgation comme une mise à jour standard requise par la Section 16, et non comme un signal de la vision à court terme de la direction sur le cours de l’action Pfizer.

Formular 4 Übersicht: Am 30.06.2025 wurden dem Vorsitzenden und CEO von Pfizer Inc. (PFE), Albert Bourla, im Rahmen des nicht finanzierten aufgeschobenen Vergütungs- und Zusatzsparplans (SSP) des Unternehmens 25 Phantom-Aktieneinheiten zu einem Referenzpreis von 24,24 USD gutgeschrieben. Jede Einheit entspricht einer Stammaktie von Pfizer, wird jedoch nach dem Ausscheiden des Geschäftsführers in bar abgewickelt und kann jederzeit in andere Planinvestitionen umgeschichtet werden.

Nach dieser routinemäßigen Gutschrift beläuft sich Bourlas gesamter Phantom-Einheitenbestand auf 718.220 Einheiten. Die Meldung enthält keine Käufe oder Verkäufe von Pfizer-Stammaktien am offenen Markt, und es gibt keine Änderung seines direkten Aktienbesitzes.

Aufgrund der unbedeutenden Größe der Zuteilung (25 Einheiten) und ihres Charakters als aufgeschobene Vergütung gilt die Transaktion als administrativ und ohne Marktauswirkung. Anleger sollten die Offenlegung als ein standardmäßiges Update gemäß Abschnitt 16 ansehen und nicht als Hinweis auf die kurzfristige Einschätzung des Managements zum Aktienkurs von Pfizer.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small, cash-settled phantom stock credit; no market trades; neutral for valuation.

The 25-unit addition is immaterial (<1 % of Bourla’s existing 718k phantom units) and involves no exchange of cash or common shares today. Because the units settle only upon separation and do not confer voting rights, the filing neither tightens nor loosens insider alignment in the short term. There is no read-through for earnings, cash flow or capital allocation, so the market impact should be negligible.

TL;DR: Routine deferred-comp grant, signals continued use of SSP, governance neutral.

Phantom stock within a non-funded plan is a typical tool to align executives with shareholders over the long horizon while deferring tax. The token 25-unit credit indicates ongoing salary deferral rather than an incentive shift. No new performance conditions or special board actions are disclosed, suggesting governance status quo. Overall, the filing carries no red flags and maintains standard transparency under Section 16.

Riepilogo del Modulo 4: Il 30/06/2025, Albert Bourla, Presidente e CEO di Pfizer Inc. (PFE), ha ricevuto 25 Phantom Stock Units a un prezzo di riferimento di 24,24 dollari nell'ambito del Piano di Compensazione Differita Non Finanziata e Risparmio Supplementare (SSP) dell'azienda. Ogni unità rappresenta una azione ordinaria di Pfizer, ma sarà liquidata in contanti dopo la cessazione del rapporto di lavoro e può essere riallocata in altri investimenti del piano in qualsiasi momento.

Dopo questa normale assegnazione, il saldo totale delle phantom unit di Bourla è di 718.220 unità. Il documento non evidenzia acquisti o vendite sul mercato aperto di azioni Pfizer, né variazioni nella sua proprietà diretta di azioni.

Considerando la dimensione insignificante della concessione (25 unità) e la natura di compensazione differita, la transazione è considerata amministrativa e senza impatto sul mercato. Gli investitori dovrebbero interpretare questa comunicazione come un aggiornamento standard richiesto dalla Sezione 16, non come un'indicazione della visione a breve termine della dirigenza sul prezzo delle azioni Pfizer.

Resumen del Formulario 4: El 30/06/2025, Albert Bourla, Presidente y CEO de Pfizer Inc. (PFE), recibió 25 Unidades de Acciones Fantasma a un precio de referencia de 24,24 dólares bajo el Plan de Compensación Diferida No Financiada y Ahorro Suplementario (SSP) de la compañía. Cada unidad representa una acción común de Pfizer, pero se liquidará en efectivo tras la separación del ejecutivo de la empresa y puede reasignarse a otras inversiones del plan en cualquier momento.

Tras esta acumulación rutinaria, el saldo total de unidades fantasma de Bourla asciende a 718,220 unidades. La presentación no revela compras o ventas en el mercado abierto de acciones comunes de Pfizer, ni cambios en su propiedad directa de acciones.

Dada la insignificancia del otorgamiento (25 unidades) y su naturaleza de compensación diferida, la transacción se considera administrativa y sin impacto en el mercado. Los inversores deben ver esta divulgación como una actualización estándar requerida por la Sección 16, no como una señal de la perspectiva a corto plazo de la gerencia sobre el precio de las acciones de Pfizer.

Form 4 요약: 2025년 6월 30일, Pfizer Inc.(PFE) 회장 겸 CEO 알버트 보를라는 회사의 비기금 이연 보상 및 추가 저축 계획(SSP)에 따라 기준 가격 24.24달러로 25개의 팬텀 스톡 유닛을 부여받았습니다. 각 유닛은 Pfizer 보통주 1주와 동일하지만, 임원이 퇴직한 후 현금으로 정산되며 언제든지 다른 투자로 재배분할 수 있습니다.

이번 정기 적립 후 보를라의 총 팬텀 유닛 잔액은 718,220 유닛입니다. 제출 서류에는 Pfizer 보통주의 시장 내 매매 내역이 없으며, 직접 보유 주식에도 변동이 없습니다.

부여 수량이 미미한 25유닛이고 이연 보상의 성격을 고려할 때, 이 거래는 행정적이며 시장에 영향을 미치지 않는 것으로 간주됩니다. 투자자들은 이 공시를 경영진의 단기 주가 전망 신호가 아닌 섹션 16에 따른 표준 업데이트로 이해해야 합니다.

Résumé du formulaire 4 : Le 30/06/2025, Albert Bourla, président-directeur général de Pfizer Inc. (PFE), s'est vu attribuer 25 unités d’actions fantômes à un prix de référence de 24,24 $ dans le cadre du Plan de compensation différée non financé et d’épargne supplémentaire (SSP) de l’entreprise. Chaque unité correspond à une action ordinaire de Pfizer, mais sera réglementée en espèces après la séparation de l’exécutif et peut être réaffectée à d’autres investissements du plan à tout moment.

Après cette attribution routinière, le solde total des unités fantômes de Bourla s’élève à 718 220 unités. Le dépôt ne révèle aucun achat ou vente sur le marché ouvert d’actions ordinaires Pfizer, et il n’y a aucun changement dans sa détention directe d’actions.

Compte tenu de la taille négligeable de cette attribution (25 unités) et de sa nature de compensation différée, la transaction est considérée comme administrative et sans impact sur le marché. Les investisseurs doivent considérer cette divulgation comme une mise à jour standard requise par la Section 16, et non comme un signal de la vision à court terme de la direction sur le cours de l’action Pfizer.

Formular 4 Übersicht: Am 30.06.2025 wurden dem Vorsitzenden und CEO von Pfizer Inc. (PFE), Albert Bourla, im Rahmen des nicht finanzierten aufgeschobenen Vergütungs- und Zusatzsparplans (SSP) des Unternehmens 25 Phantom-Aktieneinheiten zu einem Referenzpreis von 24,24 USD gutgeschrieben. Jede Einheit entspricht einer Stammaktie von Pfizer, wird jedoch nach dem Ausscheiden des Geschäftsführers in bar abgewickelt und kann jederzeit in andere Planinvestitionen umgeschichtet werden.

Nach dieser routinemäßigen Gutschrift beläuft sich Bourlas gesamter Phantom-Einheitenbestand auf 718.220 Einheiten. Die Meldung enthält keine Käufe oder Verkäufe von Pfizer-Stammaktien am offenen Markt, und es gibt keine Änderung seines direkten Aktienbesitzes.

Aufgrund der unbedeutenden Größe der Zuteilung (25 Einheiten) und ihres Charakters als aufgeschobene Vergütung gilt die Transaktion als administrativ und ohne Marktauswirkung. Anleger sollten die Offenlegung als ein standardmäßiges Update gemäß Abschnitt 16 ansehen und nicht als Hinweis auf die kurzfristige Einschätzung des Managements zum Aktienkurs von Pfizer.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Davison James E

(Last) (First) (Middle)
2000 FARMERVILLE HIGHWAY

(Street)
RUSTON LA 71270

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GENESIS ENERGY LP [ GEL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Units - Class A(1) 07/01/2025 M 2,584(1) A (2) 2,720,474 D
Common Units - Class A(1) 07/01/2025 D 2,584(1) D $16.54(2) 2,717,890 D
Common Units - Class A 1,010,835 I Terminal Services, Inc.(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Units (2) 07/01/2025 M 2,584 07/01/2025 07/01/2025 Common Units - Class A 2,584 (2) 8,705 D
Phantom Units (4)(5) 07/01/2025 A 2,388 07/01/2026 07/01/2026 Common Units - Class A 2,388 (4)(5) 11,093 D
Explanation of Responses:
1. The payment of the phantom units in cash is deemed to be a disposition of the phantom units in exchange for the acquisition of the underlying Common Units - Class A and a simultaneous disposition of the underlying Common Units - Class A to the issuer.
2. Upon vesting, the phantom units were paid in cash based on the average closing price of the Common Units - Class A for the 20 trading days immediately prior to the date of vesting.
3. The Reporting Person is the sole stockholder of Terminal Services, Inc.
4. The phantom units will be paid in cash based on the average closing price of the Common Units - Class A for the 20 trading days immediately prior to the vesting date.
5. Award includes tandem distribution equivalent rights pursuant to which the quarterly distributions paid by the partnership on each Common Unit - Class A will be accrued over the vesting period and paid quarterly.
Remarks:
James E. Davison 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Pfizer (PFE) report on the July 2 2025 Form 4?

CEO Albert Bourla received 25 Phantom Stock Units on 06/30/2025 under Pfizer’s Supplemental Savings Plan.

Were any Pfizer common shares bought or sold by the CEO?

No. No open-market purchases or sales of Pfizer common stock were reported in this filing.

How many phantom stock units does Albert Bourla now hold?

Following the transaction, Bourla’s phantom unit balance is 718,220 units.

What is a phantom stock unit in Pfizer’s SSP?

Each unit tracks one Pfizer share but is settled in cash after the executive leaves the company; it carries no voting rights.

Does the filing indicate a change in Pfizer’s executive compensation structure?

No. The credit appears to be a routine deferred-compensation accrual with no new performance terms disclosed.
Genesis Energy L P

NYSE:GEL

GEL Rankings

GEL Latest News

GEL Latest SEC Filings

GEL Stock Data

2.11B
106.40M
13.09%
73.48%
2.69%
Oil & Gas Midstream
Pipe Lines (no Natural Gas)
Link
United States
HOUSTON